Alex C. Veith , Patrick R. Carney , Aijing Wu , Brenda L. Rojas , Emmanuel Vazquez-Rivera , Mark E. Berres , Christopher Harrison , C. Dustin Rubinstein , Christopher A. Bradfield
{"title":"Retrospective analysis and decentralized distribution to improve the lifecycle of Ah receptor research assets","authors":"Alex C. Veith , Patrick R. Carney , Aijing Wu , Brenda L. Rojas , Emmanuel Vazquez-Rivera , Mark E. Berres , Christopher Harrison , C. Dustin Rubinstein , Christopher A. Bradfield","doi":"10.1016/j.bcp.2025.116874","DOIUrl":null,"url":null,"abstract":"<div><div>Scientific progress benefits from the sharing of “research assets” such as data, reagents, models, and experimental samples. To improve asset shareability, we evaluated the availability, quality, and characterization of recombinant DNA molecules, recombinant mouse models, and tissue samples described by our laboratory in ten publications spanning over thirty years. Employing state-of-the-art molecular technologies, we identified existing samples, updated their localization, generated modern sequences and maps of recombinant models, and ported the associated metadata to an internal blockchain-dependent resource using a standardized description for each asset class. We also created non-fungible tokens representing research assets on the public blockchain network Solana. In addition to providing an audit of previously reported shareable assets and improving the value of recombinant models, this re-analysis also provides evidence for the utility of extant tissue samples that may be difficult and expensive to regenerate. The results demonstrate how retrospective analysis can improve and expand upon the spectrum of shareable research assets through updates on molecular characterization and physical location, as well as improving the availability of biological samples of potential high experimental value. Moreover, the development of a decentralized ledger harboring this revised metadata provides a path to the description and tokenization of scientific assets and provides a strategy to extend the life of scientific assets even after laboratories or sources close.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"236 ","pages":"Article 116874"},"PeriodicalIF":5.3000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006295225001364","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Scientific progress benefits from the sharing of “research assets” such as data, reagents, models, and experimental samples. To improve asset shareability, we evaluated the availability, quality, and characterization of recombinant DNA molecules, recombinant mouse models, and tissue samples described by our laboratory in ten publications spanning over thirty years. Employing state-of-the-art molecular technologies, we identified existing samples, updated their localization, generated modern sequences and maps of recombinant models, and ported the associated metadata to an internal blockchain-dependent resource using a standardized description for each asset class. We also created non-fungible tokens representing research assets on the public blockchain network Solana. In addition to providing an audit of previously reported shareable assets and improving the value of recombinant models, this re-analysis also provides evidence for the utility of extant tissue samples that may be difficult and expensive to regenerate. The results demonstrate how retrospective analysis can improve and expand upon the spectrum of shareable research assets through updates on molecular characterization and physical location, as well as improving the availability of biological samples of potential high experimental value. Moreover, the development of a decentralized ledger harboring this revised metadata provides a path to the description and tokenization of scientific assets and provides a strategy to extend the life of scientific assets even after laboratories or sources close.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.